Geert Villeirs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6737226/publications.pdf Version: 2024-02-01



CFEDT VILLEIDS

#	Article	IF	CITATIONS
1	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology, 2022, 304, 342-350.	3.6	21
2	Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. Journal of Magnetic Resonance Imaging, 2021, 53, 13-22.	1.9	16
3	How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1. Acta Radiologica, 2021, 62, 839-847.	0.5	18
4	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. European Urology Oncology, 2021, 4, 868-876.	2.6	72
5	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. European Radiology, 2021, 31, 9567-9578.	2.3	34
6	Retrospective analysis of multiparametric MRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer Journal of Clinical Oncology, 2021, 39, e16535-e16535.	0.8	0
7	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. European Urology Open Science, 2021, 29, 68-76.	0.2	23
8	A Curriculum Model for Multidisciplinary Training of Midwife Sonographers in a Low Resource Setting. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 2833-2844.	1.1	2
9	Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. BMC Cancer, 2021, 21, 1113.	1.1	10
10	T-staging of prostate cancer: Identification of useful signs to standardize detection of posterolateral extraprostatic extension on prostate MRI. Clinical Imaging, 2020, 59, 1-7.	0.8	17
11	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nature Reviews Urology, 2020, 17, 41-61.	1.9	207
12	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. European Radiology, 2020, 30, 5404-5416.	2.3	185
13	Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. European Urology, 2020, 78, 307-309.	0.9	7
14	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. European Urology Oncology, 2020, 3, 145-167.	2.6	75
15	Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. European Urology, 2020, 78, 483-485.	0.9	27
16	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. , 2020, 30, 5404.		1
17	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial Journal of Clinical Oncology, 2020, 38, 10-10.	0.8	82
18	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	0.9	200

GEERT VILLEIRS

#	Article	IF	CITATIONS
19	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	1.3	4
20	The primacy of multiparametric MRI in men with suspected prostate cancer. European Radiology, 2019, 29, 6940-6952.	2.3	51
21	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
22	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. American Journal of Roentgenology, 2019, 213, 384-396.	1.0	39
23	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351.	0.9	1,270
24	Feasibility study using iodine quantification on dual-energy CT enterography to distinguish normal small bowel from active inflammatory Crohn's disease. Acta Radiologica, 2019, 60, 679-686.	0.5	26
25	A case report and a literature review of primary retroperitoneal mucinous cystadenoma: the importance of imaging in diagnosis and management. Future Oncology, 2018, 14, 2923-2931.	1.1	11
26	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e13-158.e20.	0.8	27
27	4 Weeks Versus 5ÂWeeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 866-870.	0.4	7
28	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiotherapy and Oncology, 2018, 127, 49-61.	0.3	157
29	An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. Insights Into Imaging, 2018, 9, 87-101.	1.6	69
30	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2018, 36, 446-453.	0.8	972
31	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	1.2	16
32	Editorial Comment. Urology, 2018, 113, 127-128.	0.5	0
33	Prostatic Leiomyoma – Multiparametric Prostate MRI Features. Journal of the Belgian Society of Radiology, 2018, 102, 39.	0.1	5
34	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 152.e13-152.e22.	0.8	2
35	Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European Urology, 2017, 72, 189-191.	0.9	12
36	Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile. Journal of Clinical Pathology, 2017, 70, 838-846.	1.0	18

GEERT VILLEIRS

#	Article	IF	CITATIONS
37	The T1 Hemorrhage Exclusion Sign in the Detection of Prostate Cancer at MRI. Journal of the Belgian Society of Radiology, 2017, 101, 15.	0.2	0
38	Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up. Journal of the Belgian Society of Radiology, 2016, 100, 108.	0.2	5
39	Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. Radiotherapy and Oncology, 2016, 119, 398-404.	0.3	24
40	What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?. European Radiology, 2016, 26, 1098-1107.	2.3	63
41	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. BioMed Research International, 2015, 2015, 1-6.	0.9	26
42	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology, 2015, 68, 1045-1053.	0.9	657
43	Prostate magnetic resonance spectroscopic imaging at 1.5tesla with endorectal coil versus 3.0tesla without endorectal coil: comparison of spectral quality. Clinical Imaging, 2015, 39, 636-641.	0.8	9
44	Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?. Radiotherapy and Oncology, 2014, 113, 398-403.	0.3	28
45	Role of Imaging in the Diagnosis and Management of Complete Androgen Insensitivity Syndrome in Adults. Case Reports in Radiology, 2013, 2013, 1-6.	0.5	15
46	ESUR prostate MR guidelines 2012. European Radiology, 2012, 22, 746-757.	2.3	2,176